Massimo Breccia

Pubblicazioni

Titolo Pubblicato in Anno
Clinical Characteristics at Onset and Treatment Approaches in Young and Elderly Patients with Essential Thrombocitemia (ET) in Lazio Region: Evaluation of Retrospective and Prospective Databases BLOOD 2022
Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A ``Campus CML{''} Study BLOOD 2022
Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study BLOOD 2022
Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS) BLOOD 2022
Editorial: Risk-stratification in myelodysplastic syndromes FRONTIERS IN ONCOLOGY 2022
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year follow- up of the GIMEMA CML 0307 study HAEMATOLOGICA 2022
Myelodysplastic Syndromes with Isolated 20q Deletion: A New Clinical-Biological Entity? JOURNAL OF CLINICAL MEDICINE 2022
CML-164 Dihydroorotate Dehydrogenase Inhibition Reveals Metabolic Vulnerability in Chronic Myeloid Leukemia CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2022
CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2022
Covid-19 in Philadelphia-negative myeloproliferative neoplasms: a GIMEMA survey on incidence, clinical management and vaccine LEUKEMIA 2022
Clinical utility and physician perceptions of a digital platform for electronic patient-reported outcomes monitoring in patients with hematologic malignancies in real-world practice. BLOOD 2021
Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols ACTA ONCOLOGICA 2021
New dead/H-Box helicase gene (Ddx41) mutation in an italian family with recurrent leukemia. LEUKEMIA & LYMPHOMA 2021
Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience LEUKEMIA & LYMPHOMA 2021
Therapeutic strategies in low and high-risk MDS: What does the future have to offer? BLOOD REVIEWS 2021
Early intracranial haemorrhages in acute promyelocytic leukaemia: analysis of neuroradiological and clinico-biological parameters BRITISH JOURNAL OF HAEMATOLOGY 2021
Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up LEUKEMIA & LYMPHOMA 2021
Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab ANNALS OF HEMATOLOGY 2021
Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia LEUKEMIA & LYMPHOMA 2021
Smoothened inhibitor erismodegib combined with nilotinib in patients with chronic myeloid leukemia resistant/intolerant to at least one prior tyrosine kinase inhibitor: a phase 1b study LEUKEMIA & LYMPHOMA 2021

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma